# Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome

> **NCT02553941** · PHASE1 · COMPLETED · sponsor: **Brian Jonas** · enrollment: 21 (actual)

## Conditions studied

- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndrome
- Previously Treated Myelodysplastic Syndrome
- Refractory Anemia With Excess Blasts in Transformation
- Secondary Myelodysplastic Syndrome

## Interventions

- **DRUG:** Azacitidine
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT02553941
- **Lead sponsor:** Brian Jonas
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05-17
- **Primary completion:** 2019-05-25
- **Final completion:** 2019-11-07
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2022-10-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02553941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02553941, "Ibrutinib and Azacitidine for Treatment of Higher Risk Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02553941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*